Eye infection drug IND accepted

The Investigational New Drug (IND) application for NVC-422, a molecule under investigation by NovaBay Pharmaceuticals for the treatment of eye infections, has been cleared by the FDA, triggering a development milestone payment from Alcon to NovaBay of $1 million.

The Investigational New Drug (IND) application for NVC-422, a molecule under investigation by NovaBay Pharmaceuticals for the treatment of eye infections, has been cleared by the FDA, triggering a development milestone payment from the firm's license partner Alcon to NovaBay of $1 million.

NVC-422 - a molecule in the non-antibiotic anti-infective Aganocide class - has been shown in vitro to combat bacteria (including multi-drug-resistant strains), viruses, yeasts and fungi, and has been proven safe for ocular use in previous in vivo testing. NovaBay hopes that NVC-422 will have applications against both bacterial and viral conjunctivitis, to be used topically in the eye as well as within contact lens solution.

NVC-422 is currently also under investigation for non-ocular indications, including skin infections caused by the "superbug" MRSA.

Related Videos
Trukera Medical rebranding ushers in new era of expansion into cornea market
Investigators report positive visual outcomes one year after monocular implantation of small aperture IOL
Investigating better indications and outcomes in laser refractive surgery
Avoiding errors when converting to DMEK
Related Content
© 2023 MJH Life Sciences

All rights reserved.